Biotech: Page 23
-
Doucefleur via Getty Images
SciRhom pulls in $70M for a new type of immune disease drug
The Series A round will help the startup bring its lead candidate, an antibody aimed at the protein iRhom2, into human testing by the end of 2024.
By Gwendolyn Wu • July 9, 2024 -
Joe Raedle via Getty Images
HilleVax’s norovirus vaccine ineffective in large trial of infants
Shares in HilleVax plummeted after the company reported its experimental shot failed to meet the primary and secondary goals of the Phase 2b study.
By Delilah Alvarado • July 8, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Daniel Tadevosyan via Getty Images
Ligand to buy Apeiron; Roche reports another TIGIT setback
Acquiring Apeiron will hand Ligand royalty rights on the neuroblastoma drug Qarziba. Elsewhere, CSL reported the first commercial treatment of patients in Europe with its gene therapy Hemgenix.
By BioPharma Dive staff • July 8, 2024 -
Permission granted by Myricx Bio
A London biotech raises $114M to hone a new ADC payload
Myricx Bio is developing a type of payload that it thinks could work in tumors resistant to the toxins contained in ADCs like Enhertu and Trodelvy.
By Gwendolyn Wu • July 8, 2024 -
Courtesy of CureVac
CureVac cuts jobs, licenses out vaccines to GSK
The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.
By Jacob Bell • July 3, 2024 -
Daniel Tadevosyan via Getty Images
Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit
Forbion led the startup’s Series B round. Elsewhere, Vertex got an FDA decision date for its “vanza triple” and Dupixent won a marketing green light in Europe for COPD.
By BioPharma Dive staff • July 3, 2024 -
Maddie Meyer via Getty Images
Moderna gets US funding for bird flu vaccine development
BARDA will provide Moderna with $176 million to advance late-stage testing of an H5 influenza shot, as health officials monitor animal outbreaks.
By Delilah Alvarado • July 2, 2024 -
Scott Olson via Getty Images
Eli Lilly inks another radiopharma deal, gaining option to buy startup
Under an arrangement with Radionetics, Lilly will have rights to acquire the San Diego biotechnology company for $1 billion.
By Delilah Alvarado • July 1, 2024 -
Courtesy of UniQure
UniQure, with sale of plant, outsources Hemgenix manufacturing
The gene therapy developer, which cut jobs in October, expects the sale of a Lexington, Massachusetts, facility to Genezen to lower its cash burn.
By Ned Pagliarulo • July 1, 2024 -
Marcin Klapczynski via Getty Images
With revised IPO pitch, Artiva touts ‘natural killer’ cell therapy for autoimmune disease
Like many of its cell therapy peers, Artiva, which originally sought an IPO in 2021, has shifted its strategy to ride a wave of investor interest in autoimmune disease research.
By Ben Fidler • July 1, 2024 -
Kendall Davis/BioPharma Dive
Deep Dive10 clinical trials to watch in the second half of 2024
Study results are expected for two closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs.
By BioPharma Dive staff • July 1, 2024 -
Daniel Tadevosyan via Getty Images
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
European drug regulators voted for a third time not to renew the approval of Translarna. Elsewhere, Sanofi invested in a brain disease biotech and Esperion sold royalties to help pay off a loan.
By BioPharma Dive staff • June 28, 2024 -
hapabapa via Getty Images
Alumis cuts IPO size, but nets $250M for immune drug work
Alumis’ public offering comes during an uptick in interest in immune drugs. Still, the company sold fewer shares than intended, and added a concurrent private stock issuance to boost its total haul.
By Gwendolyn Wu • June 28, 2024 -
Courtesy of Bluebird bio
2seventy slims down with sale of hemophilia assets to Novo
Novo will pay $38 million in cash under the deal, which will also see 2seventy employees working on the program transfer to the Danish drugmaker.
By Ned Pagliarulo • June 27, 2024 -
Permission granted by Biohaven Ltd.
Deep DiveThese microscopic tunnels are a goldmine for new medicines
A growing cohort of biotechs, from Biohaven to Neurocrine to Jazz, hope research on ion channels will bring them new drugs and big business — much like it has done for Vertex.
By Jacob Bell • June 27, 2024 -
Daniel Tadevosyan via Getty Images
Zealand hauls in $1B off obesity drug data; Curie.bio zeroes in on Series A’s
Zealand capitalized on a stock surge following the release of early study results. Elsewhere, U.S. regulators rejected an AbbVie medicine and another well-funded AI drug discovery startup emerged.
By BioPharma Dive staff • June 26, 2024 -
Permission granted by Geron
After 33 years, Geron’s first approval marks a turn in Nobel-winning science
The decades-long story of how a novel type of blood cancer drug went from a scientific idea to an approved product.
By Alexandra Pecci • June 26, 2024 -
Olena_T via Getty Images
Exsilio debuts with $82M, pitching a ‘leap’ forward for genetic medicine
The company claims it can address some of the field’s limitations with medicines delivered via messenger RNA and lipid nanoparticles.
By Gwendolyn Wu • June 25, 2024 -
Daniel Tadevosyan via Getty Images
Obesity drugs from Altimmune, Hengrui show potential; Lilly details Zepbound sleep apnea data
The American Diabetes Association’s annual meeting provided a forum for early trial results on several would-be weight loss drug competitors.
By BioPharma Dive staff • June 24, 2024 -
Ivan Balvan via Getty Images
Alnylam says heart drug succeeds in closely watched study
Positive results from a Phase 3 trial of vutrisiran in transthyretin amyloidosis cardiomyopathy set up a market competition with Pfizer and BridgeBio.
By Ben Fidler • Updated June 24, 2024 -
Daniel Tadevosyan via Getty Images
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead.
By BioPharma Dive staff • June 21, 2024 -
iStock / Getty Images Plus via Getty Images
Obesity drug from Zealand shows potential in early trial
Interim study data suggest the Danish drugmaker can remain in the race to develop new kinds of weight loss drugs as doctors seek alternatives to the now dominant GLP-1s.
By Jonathan Gardner • June 20, 2024 -
whitehoune via Getty Images
FDA lifts hold on PTC Huntington’s disease trial
The agency has lifted a partial trial suspension based on one-year data showing PTC’s pill suppressed a key protein associated with the disorder.
By Jonathan Gardner • June 20, 2024 -
Daniel Tadevosyan via Getty Images
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
Belharra will use its chemoproteomics technology to identify immune drugs for Sanofi. Elsewhere, Regenxbio mapped a regulatory path and Taysha shared updated results for its Rett treatment.
By BioPharma Dive staff • June 18, 2024 -
Permission granted by Kevin Trimmer/Ascidian Therapeutics
Roche partners with RNA editing biotech Ascidian
While the Swiss pharma recently pruned its neurology drug pipeline, it has shown interest in the possibilities of RNA-focused approaches like what Ascidian is exploring.
By Gwendolyn Wu • June 18, 2024
Previous
